• Publications
  • Influence
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
TLDR
Findings indicate that pharmaceutical company sponsorship of economic analyses is associated with reduced likelihood of reporting unfavorable results. Expand
Cost minimization study of image-guided core biopsy versus surgical excisional biopsy for women with abnormal mammograms.
TLDR
Image-guided core biopsy can be cost-saving compared with surgical biopsy, particularly when the mammographic abnormality is classified as low suspicion or consists of calcifications or masses, and overall for patients who underwent lumpectomy alone. Expand
Prospective Comparison of Stereotactic Core Biopsy and Surgical Excision as Diagnostic Procedures for Breast Cancer Patients
TLDR
Stereotactic core needle biopsy is the diagnostic procedure of choice for most mammographic abnormalities, however, for patients undergoing lumpectomy without axillary surgery, it is an extra invasive procedure that does not facilitate obtaining negative margins. Expand
Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
TLDR
Sensitivity analyses suggested that the costs and cost-effectiveness results would not differ markedly when evaluated over a range of assumptions, including response rate, neutropenia rate, and dosage variations. Expand
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients.
TLDR
A cost minimization analysis of treatment with intravenously administered paclitaxel or topotecan and orally administered altretamine or etoposide for epithelial ovarian cancer found cost effectiveness will likely become an important consideration in the treatment of cancer. Expand
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer.
TLDR
Out-of-pocket costs for Medicare patients without Medigap coverage were highest for altretamine, at the full cost of $4,477, whereas Medicare covered all but $83 for topotecan, $37 for paclitaxel, and $66 for etoposide. Expand
Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia.
TLDR
A cost-minimization analysis of granulocyte macrophage colony stimulating factor for AML patients > 55 to 70 years of age during an Eastern Cooperative Oncology Group Study can serve as a template for cooperative group cost analyses. Expand
Economic Analysis of Amifostine as Adjunctive Support for Patients with Advanced Head and Neck Cancer: Preliminary Results from a Randomized Phase II Clinical Trial from Germany
TLDR
The results from a randomized phase II trial indicate that selective cytoprotection with amifostine potentially offers clinical and economic benefits in patients with advanced head and neck cancer receiving radiochemotherapy. Expand
Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical Trial
TLDR
G-CSF during induction chemotherapy for elderly patients with AML had some clinical benefits, but it did not reduce the duration of hospitalization, prolong survival, or reduce the overall cost of supportive care. Expand
Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.
TLDR
Differences in study reporting and the observed differences in data generalizability may account in part for the previous finding of lower likelihood of reporting unfavorable conclusions in pharmaceutical-sponsored studies. Expand
...
1
2
...